Human medicines European public assessment report (EPAR): Eribulin Baxter, eribulin, Date of authorisation: 27/06/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Acvybra, denosumab, Date of authorisation: 17/11/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lenalidomide Accord, lenalidomide, Date of authorisation: 20/09/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Tepadina, thiotepa, Date of authorisation: 15/03/2010, Revision: 24, Status: Authorised

Agenda - Webinar on the use of platform approaches in the non-clinical and clinical domains

ICH Q14 Analytical procedure development - Scientific guideline

European Medicines Agency’s data protection notice for the operation of the Security Access Control System